Home/Filings/4/0001209191-23-032707
4//SEC Filing

Chevallard Daniel R. 4

Accession 0001209191-23-032707

CIK 0001061027other

Filed

May 25, 8:00 PM ET

Accepted

May 26, 7:29 PM ET

Size

10.2 KB

Accession

0001209191-23-032707

Insider Transaction Report

Form 4
Period: 2023-05-25
Chevallard Daniel R.
Chief Executive Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2023-05-25+6,88995,912 total
  • Sale

    Common Stock

    2023-05-25$1.42/sh3,635$5,16092,277 total
  • Exercise/Conversion

    Restricted Stock Units

    2023-05-256,88955,110 total
    Common Stock (6,889 underlying)
Footnotes (4)
  • [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.
  • [F2]The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction.
  • [F3]Represents the weighted average share price of an aggregate total of 3,635 shares sold in the price range of $1.41 to $1.42 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F4]One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

Issuer

Viracta Therapeutics, Inc.

CIK 0001061027

Entity typeother

Related Parties

1
  • filerCIK 0001706176

Filing Metadata

Form type
4
Filed
May 25, 8:00 PM ET
Accepted
May 26, 7:29 PM ET
Size
10.2 KB